The zinc finger transcription factor, KLF2, protects against COVID-19 associated endothelial dysfunction
Open Access
- 12 July 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Signal Transduction and Targeted Therapy
- Vol. 6 (1), 1-9
- https://doi.org/10.1038/s41392-021-00690-5
Abstract
Coronavirus disease 2019 (COVID-19) is regarded as an endothelial disease (endothelialitis) with its patho-mechanism being incompletely understood. Emerging evidence has demonstrated that endothelial dysfunction precipitates COVID-19 and its accompanying multi-organ injuries. Thus, pharmacotherapies targeting endothelial dysfunction have potential to ameliorate COVID-19 and its cardiovascular complications. The objective of the present study is to evaluate whether kruppel-like factor 2 (KLF2), a master regulator of vascular homeostasis, represents a therapeutic target for COVID-19-induced endothelial dysfunction. Here, we demonstrate that the expression of KLF2 was reduced and monocyte adhesion was increased in endothelial cells treated with COVID-19 patient serum due to elevated levels of pro-adhesive molecules, ICAM1 and VCAM1. IL-1β and TNF-α, two cytokines elevated in cytokine release syndrome in COVID-19 patients, decreased KLF2 gene expression. Pharmacologic (atorvastatin and tannic acid) and genetic (adenoviral overexpression) approaches to augment KLF2 levels attenuated COVID-19-serum-induced increase in endothelial inflammation and monocyte adhesion. Next-generation RNA-sequencing data showed that atorvastatin treatment leads to a cardiovascular protective transcriptome associated with improved endothelial function (vasodilation, anti-inflammation, antioxidant status, anti-thrombosis/-coagulation, anti-fibrosis, and reduced angiogenesis). Finally, knockdown of KLF2 partially reversed the ameliorative effect of atorvastatin on COVID-19-serum-induced endothelial inflammation and monocyte adhesion. Collectively, the present study implicates loss of KLF2 as an important molecular event in the development of COVID-19-induced vascular disease and suggests that efforts to augment KLF2 levels may be therapeutically beneficial.Keywords
Funding Information
- National Natural Science Foundation of China (81941022, 81530025, 82070464)
This publication has 52 references indexed in Scilit:
- Tannic acid as a plant-derived polyphenol exerts vasoprotection via enhancing KLF2 expression in endothelial cellsScientific Reports, 2017
- Experimental Lung Injury Reduces Krüppel-like Factor 2 to Increase Endothelial Permeability via Regulation of RAPGEF3–Rac1 SignalingAmerican Journal of Respiratory and Critical Care Medicine, 2017
- A smart sealed nucleic acid biosensor based on endogenous reference gene detection to screen and identify mammals on siteScientific Reports, 2017
- KLF2 and KLF4 control endothelial identity and vascular integrityJCI Insight, 2017
- The thromboprotective effect of bortezomib is dependent on the transcription factor Kruppel-like factor 2 (KLF2)Blood, 2014
- Activation of SIRT1 by resveratrol induces KLF2 expression conferring an endothelial vasoprotective phenotypeCardiovascular Research, 2009
- Kruppel-Like Factor 2 as a Novel Mediator of Statin Effects in Endothelial CellsCirculation, 2005
- Tumor Necrosis Factor Alpha-Mediated Reduction of KLF2 Is Due to Inhibition of MEF2 by NF-κB and Histone DeacetylasesMolecular and Cellular Biology, 2005
- Statins Exert Endothelial Atheroprotective Effects via the KLF2 Transcription FactorJournal of Biological Chemistry, 2005
- KLF2 Is a Novel Transcriptional Regulator of Endothelial Proinflammatory ActivationThe Journal of Experimental Medicine, 2004